On 20-21 st May 2015, more than 150 people with an interest in core outcome sets (COS) gathered at the University of Calgary in Alberta, Canada for the fifth meeting of the COMET Initiative. This was the first annual COMET meeting in North America, and the COMET Management Group are grateful to Cochrane Canada for facilitating the meeting and an excellent joint session on the second day. As well as participants from Canada and the USA, people came from Australia, Brazil, Germany, Portugal and the UK. Over the next two days, the invited plenary talks were complemented by workshops, posters and contributed presentations. Theresa Radwell (Alberta Cancer Foundation) opened the meeting, welcoming all to Calgary and introducing the importance of engaging patients within research and outcome selection. Paula Williamson (COMET Management Group) then spoke about the COMET Initiative, emphasising that COMET is keen to avoid unnecessary duplication of effort and to facilitate the development of COS. The participants were then introduced to important methodological issues in COS through a series of presentations. John Marshall (St. Michael's Hospital, Toronto) provided a critical care perspective and highlighted that mortality is not always the most important outcome from a patient perspective. Amy Hoang-Kim (University of Toronto) presented a recommendation for a minimal set of core domains for use in distal radius fracture clinical practice and research. Moving on to nephrology, Jonathan Craig and Allison Tong (University of Sydney) overviewed existing standardized outcomes, with preliminary results showing how dialysis free time was the most important outcome to haemodialysis patients. One of the novel additions in COMET V was a panel discussion showing the importance of COS to different stakeholders. John Fletcher (Canadian Medical Association Journal) described the pros and cons of COS from an editor's perspective. Jordi Pardo (OMERACT) outlined the OMERACT process for developing a COS. Carole Légaré (Health Canada) identified the problems seen by regulators because of inconsistency of safety reporting. John Marshall (Canadian Critical Care Trials Group) spoke about challenging issues faced by the critical care research community. Mike Clarke (COMET) brought all of this together by highlighting the resources that are available through COMET to assist in the development and evaluation of COS. The ensuing discussion highlighted the benefits of COS for journals, how stakeholder involvement and international harmonisation are essential to COS development, the need to consider barriers to uptake of COS for researchers, and recognition of the need for a COS that is in no way restrictive. The afternoon began with David Moher (Ottawa Hospital Research Institute) speaking about the EQUATOR network, which aims to maximise the value of research by improving conduct and reporting. David highlighted how the evaluation of reporting guidleines and COS is critical. He was followed by a series of presentations which centred around outcomes for paediatric trials. Zafira Bhaloo (University of Alberta) emphasised how the reporting of primary outcomes in pediatric trials is inadequate and encouraged higher standards for reporting and informed selection of outcomes and their measures. Michele Hamm (University of Alberta) discussed how the use of social media to identify patient-centred outcomes in child health did not result in broad reach as a stakeholder engagement strategy. Mufiza Kapadia (The Hospital for Sick Children) ended the session by stressing the importance of involving parents and children in COS development. Alongside the 17 posters that were available for viewing throughout the first day, four of the people who had submitted abstracts had been selected to give a contributed talk. These began with Carina Benstom (University Hospital RWTH Aachen) who highlighted how the problems caused by inconsistent outcome measures in clinical trials are hardly recognised. Chris Hylton (PaCER) spoke about improvements in the results of patient experiences and outcome analysis, from involving patient and community engagement researchers. Sally Crowe (Crowe Associates Ltd) continued the patient theme, by speaking about how workshops offer context and depth for talking about outcomes. The final contributed talk came from Thomas Kelley (International Consortium for Health Outcomes Measurement) who explained how ICHOM's mission is to define global standard sets of outcome measures that really matter to patients for the most relevant medical conditions. Mike Clarke (COMET Management Group) closed the first day with a presentation about COMET in Canada, which highlighted what Canada can do to increase the use of COS in research, for example by helping to persuade funders that COS should be used in research. The second day (21 st May) was shared with Cochrane Canada and the opening of their Annual Symposium. The opening of the joint session was marked by memories of Dave Sackett and his contribution to evidence based healthcare. Following a minute's silence for the many friends, colleagues and admirers of Dave to remember him, the scientific session began with Kay Dickersin (John Hopkins University) highlighting how groundwork needs to be laid in subject areas where there are a lack of COS and how new methods need to be explored for developing COS. Mike presented findings from a survey of outcomes in Cochrane Reviews, showing the wide variation in outcomes and the lack of COS, at least up to 2013. Holger Schünemann (McMaster University) closed the plenary session by providing an overview of the GRADE evidence to decision frameworks. Following a break, the participants headed off for one of three COMET workshops. Paula Williamson led the first of these, which focused on the methods for developing what to measure in COS. The workshop introduced methodological issues and considerations involved in developing COS. Workshop 2 was led by Mike Clarke and looked at how COS might be used for randomised trials and Cochrane Reviews. Bridget Young (University of Liverpool) led the third workshop providing an interactive opportunity for the participants to identify the challenges that researchers may encounter when planning to involve patients and carers in COS development. COMET V allowed a wide variety of stakeholders with an interest in COS development to meet and share experiences, findings, and plans with others. It brought together key scientists and consumers responsible for developing and implementing COS. Patient involvement emerged as a major focus of the meeting with an emphasis on engaging the relevant stakeholders early in the process of COS development. Thoughts were offered for how COMET can evolve both in Canada and the rest of the world. And, challenging questions were posed throughout the meeting, including: How can we ensure that COS are well developed in the first place? Is there a magic number of outcomes to be included in a COS and, if so, what is it? As COMET looks forward to COMET VI, it will seek to meet these challenges, guided by an International Advisory Group, which will include Peter Tugwell (University of Ottawa), one of the founders of OMERACT. The slides from COMET V presentations can be viewed at: http://www. comet-initiative.org/events/FifthCometMeeting.
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O R A L P R E S E N T A T I O N S O1
A minimum core outcome set for clinical trials on non-minimal-invasive off-or on-pump cardiothoracic surgery Carina Benstöm Method: With several studies now complete, this presentation will focus on strengths of patient-led research. The PaCER method of data collection and analysis engages patients in focus groups to define the scope and research questions (Set), followed by various data collection activities such as focus groups, questionnaires, observation, narrative interviewing (Collect), and a final (Reflect) focus group. Research protocols are negotiated in collaboration with academic researchers, ethics panels, funders and PaCER teams.
Results: PaCERs have enhanced the research community in tangible ways. Individuals involved in the experience have developed both the self-confidence and competence to be more meaningfully engaged in research outcomes which impact care protocols and the negotiation of healthcare policy. Healthcare professionals have new tools to obtain credible data that are relevant to patients. Based on examples from several recent PaCER studies, this presentation will demonstrate that patients often reveal formerly unknown commentary on how they experience current best practices and entirely refreshing views of optimal treatment, care and outcomes from the patient as consumer perspective.
Conclusion:
The patient engagement research approach will improve the results of patient experience and outcome analysis, in any clinical research area. Adding the active voice, and research minds of patients can enrich the patient engagement process in outcome research.
O3
Public engagement in outcomes development -three degrees of separation Sally Crowe * , Sandra Regan, Ann Daly Crowe Associates, Thame Oxon, OX9 3LW, UK E-mail: sally@crowe-associates.co.uk Trials 2015, 16(Suppl 3):O3
Background: This presentation will focus on a UK Cochrane funded project that explored different ways of engaging patients, the public and health practitioners in the development of outcomes for systematic reviews. It is called 'Outcomes Most Important for Patients, Public and Practitioners (OMIPPP)'. Method: Working with three Cochrane Review Groups (CRG); Airways, Ear Nose and Throat (ENT) and Pregnancy and Childbirth we focussed on outcomes for reviews in Asthma, Rhinosinusitis and Breastfeeding respectively. For each group we used a different method to engage; for asthma we facilitated a full day workshop. Working in partnership with Asthma UK, we prepared for this by gathering perspectives of asthma via a Facebook survey, and reviewing existing core outcome sets. Working in partnership with evidENT we gathered perspectives in rhinosinusitis using an online survey and experimented with social media as a way of reaching out beyond their networks as there are no relevant patient groups. We compared survey findings with existing outcomes used for reviews of chronic sinusitis. For breastfeeding we worked with the National Childbirth Trust and the Breastfeeding Network to review an existing online collection of experiences of breastfeeding called Healthtalk (http://www.healthtalk.org).
Trials 2015, Volume 16 Suppl 3 http://www.trialsjournal.com/supplements/16/S3 Healthtalk researchers reanalysed the original data for clues to outcomes. These were shared, discussed and compared with existing outcomes used in systematic reviews of breastfeeding interventions. Results: At the time of writing this abstract the project is not yet complete, however early results will be discussed. We are interested in the following aspects of evaluation; how relevant was the gathered data for systematic review outcomes? What were the cost and resource implications of each method? From a review group perspective how feasible are these methods? Has the project extended the reach of CRGs with interested public/patient and practitioner groups? How does our data compare with other outcomes exercises e.g. COMET? Methods: ICHOM was founded in 2012 to address these challenges. ICHOM brings together working groups, organised around the medical condition, consisting of patients, health professionals, researchers, outcomes measurement experts and policy makers, from all major regions of the world. Working groups follow a structured series of teleconferences, facilitated by ICHOM, with each teleconference covering a set topic, followed by a survey for working group members to complete. The end result is a globally agreed set of outcomes that reflects what matters most to most patients. ICHOM sets aim to be used in both routine clinical practice and as an endpoint in clinical studies. Results: ICHOM has now produced 12 standard sets of outcomes covering approximately 35% of the global burden of disease. These sets include: cataracts; localised and advanced prostate cancer; lower back pain; coronary artery disease; Parkinson's disease; cleft lip and palate; stroke; macular degeneration; hip and knee osteoarthritis; depression and anxiety; lung cancer. ICHOM is now forming networks of hospitals around the world, which are working together to begin measuring, benchmarking, and performing outcome comparisons and translating this into subsequent learning. Conclusion: ICHOM is working with health systems and measurement bodies all over the world to produce and implement, in clinical practice and in clinical studies, globally agreed standard sets of outcomes that reflect what matter most to patients. This will enable global outcome comparisons and translatable learning.
O4

P O S T E R P R E S E N T A T I O N S P1
Assessment of main adverse drug reactions in systematic reviews and clinical trials of heparins for surgery prophylaxis Daniela R Junqueira School of Physiotherapy, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil E-mail: danijunqueira@gmail.com Trials 2015, 16(Suppl 3):P1 Background: In September 2012, we published a Cochrane systematic review assessing the risk of heparin-induced thrombocytopenia (HIT) in postoperative patients. Together with haemorrhagic events, HIT is a main adverse reaction of heparins and its most important consequence is a paradoxical increase in the risk of thromboembolic complications. Method: We evaluated the report of HIT in Cochrane reviews of unfractionated heparin (UFH) or low molecular weight heparins (LMWH) for thromboprophylaxis after any type of surgery from the 2013 to 2015, period after the publication of a Cochrane review focused on the frequency of HIT in surgical settings. Data extraction aimed to describe how often and accurately HIT was addressed as a specific outcome (primary or secondary) with a precise definition, and how complete was the report of the included clinical trials regarding HIT. Results: Four reviews were identified, each one relating to different clinical settings: cancer patients undergoing surgery (n=1), retinal reattachment surgery (n=1), microvascular surgery for digital replantation (n=1), and major amputation of lower extremity (n=1). Only one review described HIT as secondary outcome and none of the reviews indicated the accepted definition of HIT when outlining the outcomes of interest. A total of 22 clinical trials were included in the reviews, comprising a total of 14,120 patients, but no report of HIT was described. Conclusion: Systematic reviewers need to be aware of special concepts and definitions in order to collate quality and accurate data not just related to the efficacy of the drug interventions but also in relation of its safety. Considering the relevance, bleeding and HIT should be regarded as core outcomes for the assessment of the safety of heparins. However, the complex definition and testing requirements for the diagnosis of HIT may determine significant bias in the detection and reporting of this adverse drug reaction. Background: Children's responses to medical treatments differ significantly from adults. Appropriately selecting and measuring child and family relevant outcomes when designing pediatric clinical trials is important for decision making with regards to the health of the child. However, outcomes used to measure an intervention's effectiveness in current pediatric clinical trials often lack child and family relevance, are heterogeneous across and within child health ages and diseases, and are not adequately measured with validated instruments. Furthermore, involvement of patients (children) and their proxies (usually parents) in outcomes selection is minimal. Inconsistent use of outcomes and outcomes measurement in pediatric clinical trials impairs the synthesis of evidence in systematic reviews and leads to outcome reporting bias. This high variability in outcome selection and measurement has led to a situation where child health decisions on treatment of children lack the appropriate underpinning evidence, and a subsequent inability to reach a consensus on the effectiveness and safety of a treatment. Recently, outcome selection initiatives in the general population such as OMERACT and COMET advocate homogeneity of methodology for outcome selection and measurement in trials. Method: Toronto Outcome Research in Child Health (TORCH) is an exciting new collaborative initiative that develops and employs existing and new evidence-based methods for improving outcomes selection and measurement in cohort studies and trials in children. Results and discussion: The TORCH platform raises awareness on the importance of meaningful outcomes selection and measurement in children; provides methodology to select measure and report truthful, discriminative and feasible outcomes in child health research; and supports engagement with research ethics boards, funders, journal editors and regulators to critically appraise outcomes selection, measurement and reporting in any child health research. The new TORCH platform will facilitate the translation of knowledge from the literature to bedside care, thereby improving child health outcomes while reducing the burden on the healthcare system.
P3
'Getting back to normal': using patients' lived experience to inform a core outcome set for cardiac arrest clinical trials Laura Whitehead Background: A recent review of outcome reporting in out of hospital cardiac arrest (OHCA) clinical trials detailed a lack of transparency and heterogeneity, highlighting the need to establish a core outcome set (COS) (Whitehead et al., 2015) . Moreover, the review highlighted the dominance of outcomes which focused on the pathophysiological manifestations of the event and clinicians' perspectives, with an absence of outcomes which sought to explore the patients' perspective. To ensure the development of a COS with relevance and meaning to all stakeholders -patients, clinicians and researchers, we sought to explore the views of patients and their partners to improve our understanding of the outcomes that really matter. Methods: Semi-structured interviews were conducted with OHCA patients and, where possible their partners separately to gain a better understanding of the patients' experience. Participants were recruited from a large NHS trust in the West Midlands, UK. Inclusion criteria included aged >18 years, cognitively able, and not critically ill. An interpretative phenomenological analysis was adopted.
Results: A convenience sample of eight patients (62.8 years (SD 13.6); range 41-79; n=5 male (62.5%) and three of their partners were interviewed, between 3 and 12 months post-arrest. At the time of interviews 2 had returned to work, 1 was planning a phased return to work, 4 were previously retired and 1 was previously unemployed. Analysis highlighted an overarching theme of "disruption to normality" with patients' expressing a strong desire to get back to normal. The superordinate themes which contribute to this disruption include: survival, physical function, emotional well-being, social well-being and participation and the impact on others. Conclusions: This study details an exploration of the lived experience of the survivors of cardiac arrest and their partners. It provides clear, patient-derived guidance for the health outcomes that matter to patients and which should be considered for COS inclusion.
P4
The urgent need for a multi-disciplinary core outcome set for the reporting of obstetric antiphospholipid antibody syndrome Srividhya Sankaran (2004) demonstrated diversity in published studies, making it difficult to interpret the outcomes in various subgroups with OAPS. Clinicians (and patients) are divided about the efficacy of any treatment, given the heterogeneity of the patient populations studied, endpoints, outcome measures reported and treatments used. Many of these patients are being cared for by their rheumatologist, haematologist, obstetrician and fertility specialists -who may have different recommendations concerning the need for low-molecular weight heparin (LMWH). Women who have sought fertility treatment are finding it difficult to discontinue their LMWH despite the lack of evidence for its efficacy. The lack of consensus on therapeutic measures between various clinical specialities and patients often leads to poor patient experience. Patient involvement in the decision making process in these studies have not been reported; it could be the prime motivation for clinicians to continue prescribing LMWH despite the lack of demonstrable efficacy. Hence we need to develop a core outcome set so that clinicians from various subspecialities and patients will be able to assess each of these studies in a standardised fashion. Methods: 1. A systematic literature review to produce a comprehensive list of all maternal and neonatal outcomes. 2. A Delphi technique to modify the list of outcome measures into a core set agreed by various subspecialties and patients.
Results: This proposed project is in the preparation stage. International collaboration with various subspecialties is planned. This project will benefit from the support and recommendations of COMET initiative experts. Conclusion: A consensus on core outcome set for reporting for OAPS, involving clinicians across various subspecialties (rheumatology, obstetrics, maternal-fetal medicine, fertility and haematologists) and the patients is essential for studying the effectiveness of various treatment modalities. Background: Interventional studies of pediatric acute diarrhea have used heterogeneous outcome measures, often with poor reporting of their measurement properties. Use of different measures or measures that lack sound measurement properties in trials with similar primary outcomes hampers comparison and knowledge synthesis. Objectives: In this systematic review, we evaluated the measurement properties of ten commonly used instruments to assess the severity of acute diarrhea in children. Methods: Medline, EMbase and the Cochrane library were searched using a highly sensitive search filter developed by Terwee et al. to identify studies that evaluated measurement properties. This search filter was combined with the names of ten pre-identified scales of pediatric diarrhea severity. Reference lists from included articles and the original publications for the ten diarrhea scales were also reviewed. Eligibility criteria were: 1) ability to develop or evaluate the measurement properties -i.e. content validity, construct validity, reliability or responsiveness -of a measurement instrument; 2) ability to measure severity of diarrhea/gastroenteritis; and 3) ability of the scale to be developed or adapted for the pediatric population (0-18 y/o). The methodological quality of the included studies and the results of measurement properties were appraised using checklists from the COnsensus-based Standards for the selection of health Measurement Instruments (COSMIN) group. Results: The search yielded 98 potentially relevant articles, of which only 2 articles met inclusion criteria. Studies that did not evaluate measurement properties of the identified scales or did not measure pediatric diarrhea were excluded. Both included studies evaluated the measurement properties of the "Modified Vesikari score" (MVS). Assessment of methodological quality determined that both studies were of 'poor' quality in most properties except for hypothesis testing, which was rated as 'good'. MVS was rated as positive for face and construct validity and indeterminate for internal consistency and interpretability. Conclusion: Despite their wide use, we found a disturbing lack of evidence evaluating validity and reliability of the most commonly used pediatric diarrhea severity scales. Further research with sound methodology is strongly recommended to properly evaluate the measurement properties of these scales. Moreover, to avoid heterogeneity, we encourage researchers to develop scales that measure outcomes identified in a newly developed core outcome set by the COMMENT group for clinical trials in acute diarrhea. Acknowledgement: SV receives salary support as an AIHS Health Scholar. We would like to thank Dr. Susanne K. Jones for her assistance with the database search and Dr. Caroline Terwee for her guidance with the application of COSMIN criteria
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Is reviewing trial protocols on clinicaltrials.gov a feasible method of compiling a long-list for a core outcome set? Michael Fabricius Background: There is a lag of several years between the design and registration of a trial, and the publication of results, therefore the outcome measures extracted from a SR may not represent current practice. Furthermore, carrying out a SR is a laborious and timeconsuming process. We sought to determine whether a review of trial registry records would be an efficient alternative to a SR. Methods: We carried out a SR of advanced prostate cancer (PC) trials published over the period 2008-2013 (reported separately) and then reviewed the corresponding trials registry entries for the studies included in the SR. Clinicaltrials.gov NCT registration numbers were extracted from the papers where available. Where an NCT number was not available, the registry was searched for the study. A table of primary and secondary outcome measures was compiled and compared with the published outcomes. Results: NCT numbers were available for 37/47 of the studies in the SR. Primary outcomes were stated for 30/47 studies. The primary outcome reported in the literature differed from that recorded in the registry in 6/30 studies which specified primary outcomes. Secondary outcomes were recorded for 23 studies. Nine studies reported additional secondary outcomes and seven studies did not report all pre-specified secondary outcomes. All clinician-reported outcome measures from the SR were found in the registry review. 12 studies had a quality of life (QoL) or pain endpoint, but only three of these specified an instrument. Conclusion: Despite the inconsistencies on a per-trial basis, searching the registry provides a comprehensive overview of clinician-reported outcomes used in this field. However there is a limited range of outcomes used in PC trials. The trial registry search did not yield good results for PRO data. Searching trials registries may provide an alternative to a SR although this should be validated in other disease areas. Background: The COMET Initiative recognises the expertise and crucial contribution of patients and carers in developing core outcome sets and research more generally. Core outcome sets need to include outcomes that are most relevant to patients and carers, and the best way to do this is to involve patients and carers in their development. COMET is developing resources to help patients and carers to get involved in this work. Method: In March 2014 COMET hosted a collaborative meeting between core outcome set developers, UK public involvement organisations and the COMET Initiative. The aims of the meeting were to: Raise awareness amongst attending public involvement organisations about the work of COMET; identify resources that are relevant to facilitate public involvement in the work of COMET and discuss a strategy for engaging patient organisations in the work of COMET. The COMET initiative is also developing plain language resources to support patient and public involvement in COS studies. It is also piloting a tool to help involve patients in the design of a COS study. Results: As a result of the Involving People event COMET has developed an initial Patient and Public Involvement strategy and is establishing a People and Patient Participation, Involvement and Engagement (PoPPIE) working group to take forward the strategy and action plan. Two plain language resources have so far been developed with the involvement of patients and the public, these include a summary of what core outcome sets are and the work of the COMET Initiative and a description of what a Delphi process is. Piloting is underway for the tool to support researchers in designing their core outcome set study with the involvement of patients. COMET worked collaboratively with EURO-DIS (European rare disease patient organisation) and presented a webinar about COS and COMET. Background: A COS represents an agreed minimum set of outcomes that should be measured and reported in all trials of a specific condition. The COMET (Core Outcome Measures in Effectiveness Trials) initiative aims to collate and stimulate the development and application of COS, by including data on relevant studies within a publically available internetbased resource. In recent years, there has been an interest in increasing the development of COS. Therefore, this study aimed to provide an update of a previous review, and examine the quality of development of COS. A further aim was to understand the reasons why individuals are searching the COMET database. Methods: A multi-faceted search strategy was followed, in order to identify studies that sought to determine which outcomes/domains to measure in clinical trials of a specific condition. Additionally, a pop up survey was added to the COMET website, to ascertain why people were searching the COMET database. Results: Thirty-two reports relating to 29 studies were eligible for inclusion in the review. There has been an improvement in the description of the scope of a COS and an increase in the proportion of studies using literature/systematic reviews and the Delphi technique. Clinical experts continue to be the most common group involved in developing COS, however patient and public involvement has increased. The pop-up survey revealed the most common reasons for visiting the COMET website to be thinking about developing a COS and planning a clinical trial. Conclusions: This update demonstrates that recent studies appear to have adopted a more structured approach towards COS development and public representation has increased. However, there remains a need for developers to adequately describe details about the scope of COS, and for greater public engagement. The COMET database appears to be a useful resource for both COS developers and users of COS.
P9
Development of a core set of outcomes in children with severe neurodisability and feeding tune dependency: a systematic review Mufiza Z Kapadia Background/Aim: Children with severe neuro-disability are at increased risk of feeding problems resulting in approximately half of such children being undernourished with growth failure. While gastrostomy tube feeding in such patients has been shown to improve weight gain, there is uncertainty to its impact on survival, respiratory complications, parental and child quality of life, cost, and consequently leads to potentially avoidable variability in practice. The issue of lack of standardized Trials 2015, Volume 16 Suppl 3 http://www.trialsjournal.com/supplements/16/S3 outcomes for this population could be addressed through the development of a standardized core outcome set (COS). We aim to develop an evidenced based COS for children 0-18 years with severe neuro-disability and dependent gastrostomy. Methods and Results: A systematic review was undertaken to identify all outcome measures used in studies on children with severe neuro-disability dependent on gastrostomy tube feeding. PRISMA guidelines were followed. MEDLINE, EMBASE and Cochrane Register databases were searched from their inception until March 2015. Studies included systematic reviews with/ without meta-analyses, randomised controlled trials, and observational studies. After initial screening of titles and abstracts, disagreements on the eligibility of studies were resolved through discussion. Data were extracted on study characteristics, outcomes measured, designated primary and secondary outcome(s), method of measurement, and time points at which they were measured. A thematic content analysis was undertaken to map the outcomes against the OMERACT framework that included four prespecified outcome "domains": mortality, pathophysiological manifestations, patient reported outcomes and healthcare utilization. To date, 8725 titles and abstracts are screened. A total of 1460 studies were found eligible. Final results will be presented at the meeting. Discussion: Outcomes identified through this systematic review will be used to help stakeholders reach consensus on a COS for research in children with severe neuro-disability and feeding tube dependency which could be used to enhance future research, knowledge synthesis and inform clinical practice.
